In contrast to gefitinib or erlotinib, the development of vemurafenib and dabrafenib relied on the knowledge of the occurrence of BRAF V600E mutations across multiple cancer types; therefore, many instances of the agnostic use of these kinase inhibitors were reported immediately after their invention [11,12]. This evidence concerns the gene BRAF and cancer.